<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688580</url>
  </required_header>
  <id_info>
    <org_study_id>XW10172-102</org_study_id>
    <nct_id>NCT04688580</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, and Tolerability of Various XW10172 Oral Formulations in Healthy Adult Volunteers</brief_title>
  <official_title>An Open-label, Crossover Study to Assess the Pharmacokinetics, Safety, and Tolerability of Various XW10172 Oral Immediate- and Modified-release Formulations in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XWPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XWPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of&#xD;
      various formulations of XW10172 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough concentration (Cmin)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) from 0 to time of last quantifiable concentration (AUC0-tlast)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC over the dosing interval (AUCtau)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life (t1/2)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax and AUC ratios of metabolite to XW10172</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral clearance (CL/F)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, severity, and causality of AEs</measure>
    <time_frame>Up to 14 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>XW10172</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XW10172</intervention_name>
    <description>Various formulations</description>
    <arm_group_label>XW10172</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male of female participants who are 18 to 55 years of age, inclusive.&#xD;
&#xD;
          -  Participant is willing and able to provide signed and dated written informed consent&#xD;
             to participate prior to admission to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant gastrointestinal, hepatic, renal,&#xD;
             respiratory, cardiovascular, metabolic, psychiatric, neurological, immunological, or&#xD;
             endocrine disorders, poor vision, or allergic disease including drug allergies,&#xD;
             including immediate type hypersensitivity. A history of childhood asthma that has&#xD;
             resolved is acceptable.&#xD;
&#xD;
          -  Participant who, for any reason, is deemed by the investigator to be inappropriate for&#xD;
             this study; or has any condition which would confound or interfere with the evaluation&#xD;
             of the safety, tolerability, pharmacokinetics or pharmacodynamics of the&#xD;
             investigational drug; or is unable to comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M. Canafax, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>XWPharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth A Zib</last_name>
    <phone>650-885-9682</phone>
    <email>Beth.Zib@XWPharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Evans</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

